Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effect of Dual Bronchodilation With Umeclidinium/Vilanterol on Patients With COPD, Hyperinflation and Heart Failure
Sponsor: Luis Puente Maestu
Summary
Double-blind, randomized, two-period crossover, placebo-controlled, single-center study, to determine the effect of umeclidinium/vilanterol 55/22 μg compared with placebo on the increase in left systolic chamber function during exercise in patients with COPD, lung hyperinflation and mild to moderate left ventricular dysfunction.
Official title: Phase IV, Single-center, Double Blind, Randomized, Crossover, Placebo-controlled Study, to Investigate the Effect of Dual Bronchodilation With Umeclidinium Vilanterol on Patients With COPD, Hyperinflation and Heart Failure.
Key Details
Gender
All
Age Range
40 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2021-05-21
Completion Date
2026-05-29
Last Updated
2026-09-21
Healthy Volunteers
No
Conditions
Interventions
Umeclidinium/vilanterol
Umeclidinium/vilanterol 55/22 μg inhaled once a day
Placebo
Placebo inhaled once a day
Locations (1)
Hospital General Universitario Gregorio Marañón
Madrid, Spain